Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of PHV02, a Nipah Virus Vaccine Candidate (rVSV-ΔG-EBOV GP-NiVG) in Healthy Adults

NCT06221813 is registered in ClinicalTrials.gov with Public Health Vaccines LLC as lead sponsor.

NCT NCT06221813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06221813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of PHV02, a Nipah Virus Vaccine Candidate (rVSV-ΔG-EBOV GP-NiVG) in Healthy Adults
Lead sponsor
Public Health Vaccines LLC
Phase
Phase 1
Overall status
Completed
Start date
January 26, 2024
Completion date
October 2, 2024
Enrollment
120 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nipah virus infection